NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-Based Compensation (Tables)

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2023

Stock-Based Compensation

Schedule of stock-based compensation expense


		Three Months Ended March 31,
		2023			2022
General and administrative		$	272,210		$	554,661
Research and development			44,479			398,167
Total		$	316,689		$	952,828

Schedule of stock options issued and outstanding


					Weighted-		Weighted-
					Average		Average		Total
					Exercise		Remaining		Aggregate
					Price Per		Contractual		Intrinsic
		Stock Options			Share		Life (in years)		Value
Outstanding at December 31, 2022		7,310,686			2.66
Granted		37,500			0.22
Exercised		(655,000)			0.00
Forfeited		(246,677)			6.18
Outstanding at March 31, 2023		6,446,509			2.78		6.5		$	343,101
Exercisable as of March 31, 2023		4,543,451		$	2.96		5.5		$	343,101

Schedule of key assumptions used to estimate the fair value of the stock options granted


		Three Months Ended March 31,
		2023		2022
Expected term of options (years)		5.4 - 6.1		5.3 - 6.1
Expected common stock price volatility		82.3% - 85.2%		73.8% - 77.2%
Risk-free interest rate		3.5% - 4.0%		1.4% - 2.6%
Expected dividend yield		—		—

Schedule of changes in the outstanding restricted stock


					Weighted-
					Average Grant
		Restricted Stock			Date Fair Value
		Units			Price
Unvested as of December 31, 2022			—		$	—
Granted			396,460			0.20
Forfeited			—			—
Unvested as of March 31, 2023			396,460			0.20
Total unrecognized expense remaining		$	77,178
Weighted-average years expected to be recognized over			2.1